Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
6734 Stock Overview
iXensor Co., Ltd. provides technology platform that turns smartphones into in vitro diagnostic devices through its smart color sensing technology for connected healthcare.
iXensor Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$11.00 |
52 Week High | NT$26.25 |
52 Week Low | NT$10.40 |
Beta | 0.63 |
1 Month Change | -7.95% |
3 Month Change | -32.52% |
1 Year Change | -36.78% |
3 Year Change | -60.43% |
5 Year Change | n/a |
Change since IPO | -68.02% |
Recent News & Updates
Will iXensor (GTSM:6734) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Shareholder Returns
6734 | TW Medical Equipment | TW Market | |
---|---|---|---|
7D | -0.9% | -3.4% | 0.1% |
1Y | -36.8% | -8.2% | -14.4% |
Return vs Industry: 6734 underperformed the TW Medical Equipment industry which returned -8.2% over the past year.
Return vs Market: 6734 underperformed the TW Market which returned -14.4% over the past year.
Price Volatility
6734 volatility | |
---|---|
6734 Average Weekly Movement | 8.6% |
Medical Equipment Industry Average Movement | 5.2% |
Market Average Movement | 5.1% |
10% most volatile stocks in TW Market | 8.4% |
10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6734 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6734's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | n/a | Carson Chen | https://www.ixensor.com |
iXensor Co., Ltd. provides technology platform that turns smartphones into in vitro diagnostic devices through its smart color sensing technology for connected healthcare. The company’s PixoTest technology uses the lighting and image sensing module of the smartphone to detect the color change reaction on the immunoassay or colorimetric strip. It offers PixoTest Blood Glucose Monitoring System and PixoTest POCT System for chronic diseases management; Eveline Smart Fertility System and Eveline Care Telehealth Platform for women’s health management; and PixoTest COVID-19 Rapid Antigen Test for infectious disease management, as well as PixoHealth Pass Admin app and Web portal.
iXensor Fundamentals Summary
6734 fundamental statistics | |
---|---|
Market Cap | NT$603.21m |
Earnings (TTM) | -NT$73.08m |
Revenue (TTM) | NT$24.79m |
24.3x
P/S Ratio-8.3x
P/E RatioIs 6734 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6734 income statement (TTM) | |
---|---|
Revenue | NT$24.79m |
Cost of Revenue | NT$20.17m |
Gross Profit | NT$4.62m |
Other Expenses | NT$77.70m |
Earnings | -NT$73.08m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -1.33 |
Gross Margin | 18.63% |
Net Profit Margin | -294.75% |
Debt/Equity Ratio | 0% |
How did 6734 perform over the long term?
See historical performance and comparisonValuation
Is 6734 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6734?
Other financial metrics that can be useful for relative valuation.
What is 6734's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | NT$603.21m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 23.8x |
Enterprise Value/EBITDA | -7.7x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6734's PS Ratio compare to its peers?
6734 PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.8x | ||
6493 Ttbio | 1.7x | n/a | NT$529.1m |
4188 AmCad BioMed | 9.6x | n/a | NT$878.2m |
1781 Health & Life | 0.9x | n/a | NT$666.1m |
6730 Lagis Enterprise | 2.9x | n/a | NT$1.1b |
6734 iXensor | 24.3x | n/a | NT$603.2m |
Price-To-Sales vs Peers: 6734 is expensive based on its Price-To-Sales Ratio (24.3x) compared to the peer average (3.8x).
Price to Earnings Ratio vs Industry
How does 6734's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Sales vs Industry: 6734 is expensive based on its Price-To-Sales Ratio (24.3x) compared to the TW Medical Equipment industry average (2.5x)
Price to Sales Ratio vs Fair Ratio
What is 6734's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 24.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6734's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6734 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6734's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6734's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is iXensor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.4%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iXensor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine iXensor's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Past Performance
How has iXensor performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
6.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6734 is currently unprofitable.
Growing Profit Margin: 6734 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6734 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare 6734's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6734 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.7%).
Return on Equity
High ROE: 6734 has a negative Return on Equity (-128.23%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is iXensor's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6734's short term assets (NT$56.7M) exceed its short term liabilities (NT$16.6M).
Long Term Liabilities: 6734 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6734 is debt free.
Reducing Debt: 6734 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6734 has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 6734 is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Dividend
What is iXensor current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6734's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6734's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6734's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6734's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6734 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Carson Chen
no data
Tenure
Dr. Carson Chen Ph.D. is Chief Executive Officer & Co-Founder of iXensor Co., Ltd. Dr. Chen is a visionary leader with strong business acumen, a proven track record of innovation success, and a solid under...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Top Shareholders
Company Information
iXensor Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: iXensor Co., Ltd.
- Ticker: 6734
- Exchange: TPEX
- Founded: 2012
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: NT$603.206m
- Shares outstanding: 54.84m
- Website: https://www.ixensor.com
Location
- iXensor Co., Ltd.
- No.9, Aly. 2, Ln. 35
- 6th Floor
- Taipei
- 11492
- Taiwan
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/07 00:00 |
End of Day Share Price | 2022/08/05 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.